patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.
Item
patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up.
boolean
C0021430 (UMLS CUI [1])
C0248719 (UMLS CUI [2])
hypertension
Item
mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmhg measured by manual cuff sphygmomanometer
boolean
C0020538 (UMLS CUI [1])
mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff
Item
mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff
boolean
C0005823 (UMLS CUI [1])
a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg
Item
a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg
boolean
C0005823 (UMLS CUI [1])
age
Item
age 18 or older
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
patient's written informed consent in accordance with gcp (good clinical practice) and local legislation
boolean
C0021430 (UMLS CUI [1])
patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial
Item
patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial
boolean
C1623258 (UMLS CUI [1])
patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
Item
patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
patients who discontinued the preceding telmisartan clinical trial due to an adverse event
Item
patients who discontinued the preceding telmisartan clinical trial due to an adverse event
boolean
C2348568 (UMLS CUI [1])
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
Item
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])